This paper introduces a framework attributing Post-SSRI, Post-Finasteride, Post-Retinoid, and an unnamed sexual dysfunction syndrome to downregulated estrogen receptor activity, potentially guiding future treatments in sexual medicine.
8 citations
,
October 2021 in “The international journal of risk and safety in medicine” This paper describes the development of diagnostic criteria for several enduring sexual dysfunction conditions following the use of certain medications, highlighting common sexual and non-sexual symptoms.
28 citations
,
September 2014 in “Journal of Veterinary Internal Medicine” This study found that the novel drug VDC-1101 showed a 45% objective response rate in treating canine cutaneous T-cell lymphoma, offering a potential treatment option for this challenging disease.